Sima Porten (@simaporten) 's Twitter Profile
Sima Porten

@simaporten

urologist

ID: 3433354607

calendar_today20-08-2015 22:04:46

555 Tweet

1,1K Followers

578 Following

Sanam Ladi Seyedian (@sanamladi) 's Twitter Profile Photo

Women's sexual health after RC is often overlooked. Many wished for more guidance on self-pleasure and intimacy post-op. Physical and mental barriers can hinder sexual activity, leaving women feeling disappointed. USC Urology UCSFUrology Society of Urologic Oncology Amer. Urol. Assn.

Women's sexual health after RC is often overlooked. Many wished for more guidance on self-pleasure and intimacy post-op. Physical and mental barriers can hinder sexual activity, leaving women feeling disappointed.
<a href="/USC_Urology/">USC Urology</a> <a href="/UCSFUrology/">UCSFUrology</a> <a href="/UroOnc/">Society of Urologic Oncology</a> <a href="/AmerUrological/">Amer. Urol. Assn.</a>
Max Kates (@maxkates) 's Twitter Profile Photo

A Phase II Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder | Journal of Urology Andrew Gabrielson Sunil Patel MD Trinity J. Bivalacqua Brad Marxkors (Smith) auajournals.org/doi/abs/10.109…

Lindsay Hampson (@lindsayahampson) 's Twitter Profile Photo

💫Immensely proud of our UCSFUrology fellows, residents, students, and visiting students for their impressive presence at #AUA24! 💫 👀 Please look out for these amazing individuals - we'll be sharing reminders along the way!

💫Immensely proud of our <a href="/UCSFUrology/">UCSFUrology</a> fellows, residents, students, and visiting students for their impressive presence at #AUA24! 💫

👀 Please look out for these amazing individuals - we'll be sharing reminders along the way!
Sia Daneshmand, M.D. (@siadaneshmand) 's Twitter Profile Photo

Good day for #bladdercancer BOND-3 results presented by Mark Tyson showing 75.2% CR at anytime for pts with BCG unresponsive disease. Over half of non responders converted to CR with repeat dosing. 96.7% PFS@12 mos. More trials to come through Society of Urologic Oncology Roger Li CG Oncology, Inc.

Good day for #bladdercancer BOND-3 results presented by <a href="/MarkTysonMD/">Mark Tyson</a> showing 75.2% CR at anytime for pts with BCG unresponsive disease. Over half of non responders converted to CR with repeat dosing. 96.7% PFS@12 mos. More trials to come through <a href="/UroOnc/">Society of Urologic Oncology</a>  <a href="/UrogerliMD/">Roger Li</a> <a href="/cgoncology/">CG Oncology, Inc.</a>
Carissa Chu (@cchumd) 's Twitter Profile Photo

Sima Porten UCSFUrology presents Ph III SUNRISE 5 trial on papillary only BCG unresponsive NMIBC - evaluating TAR-200 vs intravesical chemotherapy now open and enrolling globally 👏🏼

<a href="/SimaPorten/">Sima Porten</a> <a href="/UCSFUrology/">UCSFUrology</a> presents Ph III SUNRISE 5 trial on papillary only BCG unresponsive NMIBC  - evaluating TAR-200 vs intravesical chemotherapy now open and enrolling globally 👏🏼
Ashish M. Kamat, MD, MBBS (@urodocash) 's Twitter Profile Photo

The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC) Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place #AUA24 #EAU24 #IBCG24 #ASCO24 Designed by Amanda Myers

The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place  #AUA24 #EAU24 #IBCG24 #ASCO24

Designed by <a href="/AmandaMyersMD/">Amanda Myers</a>
Laura Bukavina (@laurabukavinamd) 's Twitter Profile Photo

The NTACT residual disease test, eloquently presented by @scientistatlrge published in JCO Precision Oncology. .Remarkably, over 50% of patients without visible residual disease had positive mutations, indicative of field cancerization—mutations present in adjacent normal tissue WITHOUT

The NTACT residual disease test, eloquently presented by @scientistatlrge  published in <a href="/JCOPO_ASCO/">JCO Precision Oncology</a>. .Remarkably, over 50% of patients without visible residual disease had positive mutations, indicative of field cancerization—mutations present in adjacent normal tissue WITHOUT
Rana McKay, MD, FASCO (@drranamckay) 's Twitter Profile Photo

The most inspirational talk I have heard in a long time. You can make a difference! Tell the people you love that they matter everyday! #WorldGU24

UChicago Urology Residency (@uchicagouro) 's Twitter Profile Photo

Last month Scott Eggener and PGY5 Kristina Gam traveled to Gulu, Uganda with Drs. Porten, Large, and Yuen as part of IVUmed and in collaboration with Uganda Cancer Institute. Here are some photos 📸 looking back at the memorable week with a superstar team!

Last month <a href="/uroegg/">Scott Eggener</a> and PGY5 <a href="/CTuroGam/">Kristina Gam</a> traveled to Gulu, Uganda with Drs. Porten, Large, and Yuen as part of <a href="/IVUmed/">IVUmed</a> and in collaboration with Uganda Cancer Institute. Here are some photos 📸 looking back at the memorable week with a superstar team!
Stacy Loeb, MD (@loebstacy) 's Twitter Profile Photo

How amazing to be lecturing on urologic oncology in Argentina with my college best friend Sima Porten 🙏🏼 If you told me this 20 years ago I never would have believed it! Thanks Gonzalo Vitagliano Pablo Contreras for the invitation! #ILookLikeAUrologist #O&EHA2024 🇦🇷

How amazing to be lecturing on urologic oncology in Argentina with my college best friend <a href="/SimaPorten/">Sima Porten</a> 🙏🏼 If you told me this 20 years ago I never would have believed it! Thanks <a href="/DrVitagliano/">Gonzalo Vitagliano</a> <a href="/PabloNContreras/">Pablo Contreras</a> for the invitation! #ILookLikeAUrologist #O&amp;EHA2024 🇦🇷